RESUMO
This paper deals with the interaction between zein (the main protein component of corn grain) and water. It induces macroscopic properties changes and may allow for the understanding of the basis of zein endosperm structure: vitreous endosperm is compact and floury endosperm is porous, giving the endosperm its hard and soft textures, respectively. In that aim porous pills made by compaction of zein powder submitted to different hydration/dehydration processes have been prepared and studied. In particular, imbibition measurements of a pure-water drop deposited onto a zein pill were performed. Also, desiccation of a zein pill previously imbibed induces strong mechanical stresses leading to crack formation and/or large deformations.
Assuntos
Proteínas de Plantas/química , Tensoativos/química , Zeína/química , Mecânica , Porosidade , Estresse Mecânico , Propriedades de Superfície , Fatores de TempoRESUMO
Bone cancer pain most commonly occurs when tumors originating in breast, prostate, or lung metastasize to long bones, spinal vertebrae, and/or pelvis. Primary and metastatic cancers involving bone account for approximately 400,000 new cancer cases per year in the United States alone, and >70% of patients with advanced breast or prostate cancer have skeletal metastases. Whereas pain resulting from bone cancer can dramatically impact an individual's quality of life, very little is known about the mechanisms that generate and maintain this pain. To begin to define the mechanisms that give rise to advanced bone cancer pain, osteolytic 2472 sarcoma cells or media were injected into the intramedullary space of the femur of C3H/HeJ mice, and the injection hole was sealed using dental amalgam, confining the tumor cells to the bone. Twelve days after injection of 2472 tumor cells, animals showed advanced tumor-induced bone destruction of the injected femur, bone cancer pain, and a stereotypic set of neurochemical changes in the spinal cord dorsal horn that receives sensory inputs from the affected femur. Administration of osteoprotegerin, a naturally secreted decoy receptor that inhibits osteoclast maturation and activity and induces osteoclast apoptosis, or vehicle was begun at 12 days, when significant bone destruction had already occurred, and administration was continued daily until day 21. Ongoing pain behaviors, movement-evoked pain behaviors, and bone destruction were assessed on days 10, 12, 14, 17, and 21. The neurochemistry of the spinal cord was evaluated at days 12 and 21. Results indicated that osteoprotegerin treatment halted further bone destruction, reduced ongoing and movement-evoked pain, and reversed several aspects of the neurochemical reorganization of the spinal cord. Thus, even in advanced stages of bone cancer, ongoing osteoclast activity appears to be involved in the generation and maintenance of ongoing and movement-evoked pain. Blockade of ongoing osteoclast activity appears to have the potential to reduce bone cancer pain in patients with advanced tumor-induced bone destruction.
Assuntos
Neoplasias Ósseas/complicações , Glicoproteínas/farmacologia , Dor/tratamento farmacológico , Animais , Neoplasias Ósseas/patologia , Modelos Animais de Doenças , Masculino , Camundongos , Camundongos Endogâmicos C3H , Neurônios Aferentes/metabolismo , Neurônios Aferentes/fisiologia , Osteoclastos/efeitos dos fármacos , Osteoclastos/fisiologia , Osteólise/complicações , Osteólise/tratamento farmacológico , Osteólise/etiologia , Osteoprotegerina , Dor/etiologia , Proteínas Proto-Oncogênicas c-fos/biossíntese , Receptores Citoplasmáticos e Nucleares , Receptores do Fator de Necrose Tumoral , Sarcoma Experimental/complicações , Sarcoma Experimental/patologia , Medula Espinal/efeitos dos fármacos , Medula Espinal/patologiaRESUMO
Bone cancer pain is common among cancer patients and can have a devastating effect on their quality of life. A chief problem in designing new therapies for bone cancer pain is that it is unclear what mechanisms drive this distinct pain condition. Here we show that osteoprotegerin, a secreted 'decoy' receptor that inhibits osteoclast activity, also blocks behaviors indicative of pain in mice with bone cancer. A substantial part of the actions of osteoprotegerin seems to result from inhibition of tumor-induced bone destruction that in turn inhibits the neurochemical changes in the spinal cord that are thought to be involved in the generation and maintenance of cancer pain. These results demonstrate that excessive tumor-induced bone destruction is involved in the generation of bone cancer pain and that osteoprotegerin may provide an effective treatment for this common human condition.